{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:05:52Z","timestamp":1773954352830,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.tracli.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T19:14:30Z","timestamp":1550862870000},"page":"112-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease"],"prefix":"10.1016","volume":"26","author":[{"given":"R.","family":"Balbuena-Merle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Hendrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2019.02.003_bib0225","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.15182","article-title":"Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database","volume":"181","author":"Karafin","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0230","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2013-03-490623","article-title":"High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors","volume":"122","author":"Chou","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.02.003_bib0235","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.24188","article-title":"Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion","volume":"90","author":"Nickel","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0240","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/trf.12348","article-title":"Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME)","volume":"54","author":"Vichinsky","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0245","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3324\/haematol.2017.175752","article-title":"Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome","volume":"102","author":"Singhal","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2019.02.003_bib0250","first-page":"216","article-title":"A prospective study of the incidence of red cell allo-immunisation following transfusion","volume":"71","author":"Redman","year":"1996","journal-title":"Vox Sanguinis"},{"key":"10.1016\/j.tracli.2019.02.003_bib0255","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1537-2995.1995.351196110898.x","article-title":"Low incidence of red cell and HLA antibody formation by bone marrow transplant patients","volume":"35","author":"Abou-Elella","year":"1995","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3324\/haematol.2016.152074","article-title":"Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization","volume":"102","author":"Evers","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2019.02.003_bib0265","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/trf.13704","article-title":"Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence","volume":"56","author":"Stack","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0270","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MOH.0000000000000462","article-title":"Delayed haemolytic and serologic transfusion reactions: pathophysiology, treatment and prevention","volume":"25","author":"Siddon","year":"2018","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0275","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/trf.12251","article-title":"Record fragmentation due to transfusion at multiple health care facilities: a risk factor for delayed hemolytic transfusion reactions","volume":"54","author":"Unni","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0280","unstructured":"(FDA) US Dept of Health and Human Services. Fatalities Reported to the FDA Following Blood Collection. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/SafetyAvailability, accessed November 2018."},{"key":"10.1016\/j.tracli.2019.02.003_bib0285","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1537-2995.2008.02014.x","article-title":"The persistence and evanescence of blood group alloantibodies in men","volume":"49","author":"Tormey","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0290","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2018.194670","article-title":"Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease","author":"Chonat","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2019.02.003_bib0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/trf.13379","article-title":"Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series","volume":"56","author":"Nickel","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0300","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/trf.12940","article-title":"Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival","volume":"55","author":"Telen","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0305","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1182\/bloodadvances.2017007898","article-title":"Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia","volume":"1","author":"Chou","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.tracli.2019.02.003_bib0310","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood-2018-05-851360","article-title":"RH genotype matching for transfusion support in sickle cell disease","volume":"132","author":"Chou","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.02.003_bib0315","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/voxs.12296","article-title":"Immune Regulation of sickle Cell Alloimmunization","volume":"12","author":"Yazdanbakhsh","year":"2017","journal-title":"ISBT Sci Ser"},{"key":"10.1016\/j.tracli.2019.02.003_bib0320","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.13123","article-title":"Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell disease","volume":"168","author":"Fasano","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0325","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MOH.0000000000000277","article-title":"Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside","volume":"23","author":"Hendrickson","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0330","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/asheducation-2016.1.446","article-title":"Understanding red blood cell alloimmunization triggers","author":"Hendrickson","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.tracli.2019.02.003_bib0335","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/bjh.14307","article-title":"Red cell alloimmunisation in patients with different types of infections","volume":"175","author":"Evers","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0340","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1046\/j.1537-2995.1997.37497265337.x","article-title":"Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients\u2019 red cells.[see comment]","volume":"37","author":"King","year":"1997","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0345","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1542\/peds.111.6.e661","article-title":"Delayed hemolytic transfusion reaction\/hyperhemolysis syndrome in children with sickle cell disease","volume":"111","author":"Talano","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.tracli.2019.02.003_bib0350","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1537-2995.2009.02199.x","article-title":"Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death","volume":"49","author":"Chadebech","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0355","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24908","article-title":"Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease","author":"Narbey","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0360","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ajh.24460","article-title":"Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes","volume":"91","author":"Habibi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0365","first-page":"206","article-title":"The first reported case of anti-Dob causing an acute hemolytic transfusion reaction","volume":"66","author":"Halverson","year":"1994","journal-title":"Vox Sang"},{"key":"10.1016\/j.tracli.2019.02.003_bib0370","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1046\/j.1537-2995.1998.38111299056310.x","article-title":"Difficulties in identifying antibodies in the Dombrock blood group system in multiply alloimmunized patients","volume":"38","author":"Strupp","year":"1998","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0375","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1537-2995.2006.00707.x","article-title":"Recurrent acute hemolytic transfusion reactions by antibodies against Doa antigens, not detected by cross-matching","volume":"46","author":"Baumgarten","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0380","doi-asserted-by":"crossref","first-page":"16459","DOI":"10.1074\/jbc.M110.206136","article-title":"Heme interacts with c1q and inhibits the classical complement pathway","volume":"286","author":"Roumenina","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.tracli.2019.02.003_bib0385","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2013-03-489245","article-title":"Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome","volume":"122","author":"Frimat","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.02.003_bib0390","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4103\/njcp.njcp_412_17","article-title":"Complement Levels in Nigeria Patients with Sickle Cell Anaemia in the Asymptomatic State","volume":"21","author":"Okeke","year":"2018","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.tracli.2019.02.003_bib0395","first-page":"1326","article-title":"Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients","volume":"92","author":"Wang","year":"1993","journal-title":"J Clin Invest 1993;"},{"key":"10.1016\/j.tracli.2019.02.003_bib0400","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood.V83.3.842.842","article-title":"Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation","volume":"83","author":"Test","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.02.003_bib0405","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/trf.14431","article-title":"Whole-exome sequencing of sickle cell disease patients with hyperhemolysis syndrome suggests a role for rare variation in disease predisposition","volume":"58","author":"Mwesigwa","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0410","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2015-09-669770","article-title":"Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients","volume":"127","author":"Dumas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.02.003_bib0415","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1111\/trf.13144","article-title":"Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab","volume":"55","author":"Boonyasampant","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0420","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tracli.2017.05.016","article-title":"Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment","volume":"24","author":"Pirenne","year":"2017","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0425","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjh.14609","article-title":"Prevalence and risk factors for red blood cell alloimmunization in 175 children with sickle cell disease in a French university hospital reference centre","volume":"177","author":"Allali","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tracli.2019.02.003_bib0430","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1537-2995.1996.36696269503.x","article-title":"Studies of antibodies in the sera of patients who have made red cell autoantibodies","volume":"36","author":"Issitt","year":"1996","journal-title":"Transfusion"},{"key":"10.1016\/j.tracli.2019.02.003_bib0435","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/0973-6247.137438","article-title":"Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: Study on 319 patients","volume":"8","author":"Dhawan","year":"2014","journal-title":"Asian J Transfusion Sci"},{"key":"10.1016\/j.tracli.2019.02.003_bib0440","author":"U.S Department of Health and Human Services, National Institutes of Health","year":"2014","journal-title":"Evidence-based management of sickle cell disease: expert panel report"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S124678201930031X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S124678201930031X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:38:02Z","timestamp":1761129482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S124678201930031X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S124678201930031X"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2019.02.003","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}